lot of companies get vaccines route instead of drug route for a reason. If you look at the number of drugs approved in last 30 years, you will get the answer, why it is getting difficult for MSB.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-42
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $966.6K | 1.047M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 140895 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 67838 | 74 |
View Market Depth
| Last trade - 14.41pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |